By Abhishek Vishnoi
MUMBAI (Reuters) - The BSE Sensex slumped more than 2 percent on Monday, marking its biggest daily fall since September 3 as a rout in emerging markets hit blue chips, while lenders were hurt further by caution ahead of the Reserve Bank of India's policy review.
The Sensex has fallen 3.1 percent since hitting a record closing high on Thursday, reflecting how sentiment has changed suddenly as the U.S. Federal Reserve is poised to continue reducing its monetary stimulus and as fears rise of an economic slowdown in China.
The global factors have raised fears that foreign investors will start exiting India after buying a net $20.10 billion of shares in 2013.
Foreign institutional investors sold shares worth 1.96 billion rupees on Friday but are still net buyers of 32.77 billion rupees this year.
Investors are also cautious ahead of the RBI's policy review on Tuesday.
More From This Section
Although analysts still think the central bank will keep interest rates on hold, expectations of a rate hike are increasing after the central bank made fighting high consumer inflation a priority.
The NSE volatility index, considered at times as an investor fear gauge, surged 17 percent, reflecting the uncertainty.
"The market's reaction to the global contagion will be short-lived due to improvements in our current account. I think the RBI would support growth tomorrow and not just focus on inflation," said Deven Choksey, managing director at K R Choksey Securities.
The Sensex slumped 2.02 percent, or 426.11 points, to end at 20,707.45, marking its biggest daily decline since a 3.45 percent fall on September 3 when domestic shares were hit by worries about military tensions in Syria.
The broader Nifty lost 2.09 percent, or 130.90 points, to end at 6,135.85, closing below the technically important 6,200 level.
Among blue chip shares, Reliance Industries
Banks were among the leading decliners ahead of the RBI's policy review. ICICI Bank Ltd
Meanwhile, Tata Motors Ltd
Ranbaxy Laboratories Ltd
Among stocks that gained, Glenmark Pharmaceuticals Ltd
Opto Circuits
Opto officials were not immediately reachable for comments.
(Editing by Anupama Dwivedi)